|Bid||225.15 x 900|
|Ask||228.95 x 1000|
|Day's Range||225.11 - 231.53|
|52 Week Range||216.12 - 358.41|
|Beta (3Y Monthly)||1.39|
|PE Ratio (TTM)||8.42|
|Earnings Date||Oct 21, 2019 - Oct 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||258.00|
Exxon Mobil Corp, Schlumberger Ltd., Biogen Inc. and Honda Motor Co. Ltd. have declined to their respective 3-year lows Continue reading...
The big shareholder groups in Biogen Inc. (NASDAQ:BIIB) have power over the company. Insiders often own a large chunk...
Biogen (BIIB) is a major biopharmaceutical company specializing in treatments for multiple sclerosis (about 60% of sales) and spinal muscular atrophy (about 15% of sales), notes George Putnam, editor of The Turnaround Letter.
SMA Identified program offers genetic testing for SMA at no charge to individuals in the U.S. CAMBRIDGE, Mass. and SAN FRANCISCO, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (BIIB) and Invitae Corporation (NVTA) today announced that SMA STAT, a new, rapid-turnaround genetic test for spinal muscular atrophy (SMA), will be offered at no charge to individuals in the U.S. as part of the SMA Identified program. The SMA STAT test reduces the time needed for genetic testing to help confirm a definitive diagnosis of SMA from 21 to four days, enabling individuals and physicians to plan and begin treatment earlier for what is often a life-threatening disease.
AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives FDA approval for treating rheumatoid arthritis under the trade name of Rinvoq. Shares up.
Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
PDL BioPharma's (PDLI) earnings exceed estimates in the second quarter of 2019. However, the company generates negative revenues due to a change in the fair value of royalty rights.
After years as a rare disease drugmaker, Sarepta Therapeutics Inc. is expanding into a neurological disease that affects millions of people worldwide and has been dominated for years by its Cambridge neighbor, Biogen Inc.
The challenge raised a "mind-boggling" amount of money for ALS research, but those funds were quickly spent.
Sure, the Cambridge biotech giant Biogen has stumbled and recovered before. But the question now on many people’s minds is whether CEO Michel Vounatsos can revive the company yet again.
We last held shares of Biogen Idec Inc. (BIIB) in 2010; the biotech company is known for selling drugs and therapies to combat many degenerative nerve diseases, blood conditions and autoimmune diseases, notes David Fried, editor of The Buyback Letter.
The following is our latest Fund Analyst Report for PRIMECAP Odyssey Stock POSKX . Morningstar Premium Members have access to full analyst reports such as this for more than 1,000 of the largest and best mutual funds. Primecap Odyssey Stock retains a Morningstar Analyst Rating of Gold.